Skip to main content
  • Saved

made a Post

Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy

Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy

Source : https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0705-y

Immunotherapy using checkpoint inhibitors, especially PD-1/PD-L1 inhibitors, has now evolved into the most promising therapy for cancer patients. However, most of these inhibitors are monoclonal antibodies, and their large size may limit their tumor penetration, leading to suboptimal efficacy. As a result, there has been a growing interest in developing low-molecular-weight checkpoint inhibitors.

Sign In or Register Today to Access This Content